CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin.

While technological innovation often dominates market attention, a growing number of investors are seeking growth opportunities in less crowded sectors. The global leisure travel industry, currently in a strong recovery, offers such an alternative, with the cruise segment demonstrating significant strength.

LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st.

VANCOUVER, BC , May 22, 2025 /PRNewswire/ - Today, West Fraser Timber Co. Ltd. ("West Fraser" or the "Company") (TSX: WFG) (NYSE: WFG) released its 2024 Sustainability Report, Building Together: People and Partnerships.

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor targeted imaging agents, announced new data being presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results demonstrate that using intraoperative molecular imaging (IMI) with abenacianine for injection (VGT-309), the company's investigational tumor-targeted fluorescent imaging agent, during lung surgery has the potential to help optimize tumor resectio.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1.

Major U.S. equities indexes were mixed on Thursday after the House of Representatives passed a far-reaching budget bill that includes significant tax cuts and reduced spending on government health care and food assistance programs. The proposed budget will now head to the Senate, where it could see changes and amendments.

Vital Energy, Inc. is now projected to generate $267 million in 2025 free cash flow. This is helped by its hedges, with around 94% of its 2H 2025 oil production hedged. Vital has significantly fewer 2026 hedges, so it is relying on service cost decreases to lower its corporate breakeven point.

Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset

First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM).

ELKHART, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- THOR Industries, Inc. (NYSE: THO) today announced that the date for its fiscal 2025 third quarter earnings release will be on Wednesday, June 4, 2025, before the market opens.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / WHY: New York, N.Y., May 22, 2025.

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide-ranging effect of treatment with XTANDI (enzalutamide) plus ADT across various patient subgroups, …

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced multiple presentations related to its oncology programs at upcoming medical conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting, and the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149846&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.

Amended Terms with Alumni Capital Reinforce Disciplined Capital Deployment and Long-Term Growth Priorities Amended Terms with Alumni Capital Reinforce Disciplined Capital Deployment and Long-Term Growth Priorities

VANCOUVER, BC , May 22, 2025 /PRNewswire/ - Wheaton Precious Metals™ Corp. ("Wheaton" or the "Company") today published both its 2024 Sustainability Report and 2024 Climate Change Report. "Wheaton's 2024 Sustainability and Climate Change Reports highlight how we integrate ESG considerations into our decision making and business operations, as well as our comprehensive sustainability strategy that seeks to support the mining industry to deliver essential commodities and materials in a sustainable manner," said Randy Smallwood, Wheaton's President and Chief Executive Officer.

The human-resources software company logged higher first-quarter revenue and reaffirmed its full-year outlook as sales in its key subscription segment continue to rise.

Advance Auto Parts' Q1 operational performance remained weak with continued losses, margin challenges, and rising overhead costs. Turnaround efforts, like store closures and the Worldpac sale, improved the balance sheet but haven't yet translated into improved profitability or positive free cash flow. I am not convinced that the company will be able to meet its 2025 guidance given weak margins, negative sales trends, and past lack of execution.

The software company now expects full-year revenue between $6.925 billion and $6.995 billion, up $30 million on either end of the range. Shares rose in after-hours trading.